Talasaz AmirAli 4

What Happened

• Talasaz AmirAli, CEO of Guardant Health, had restricted stock units convert/exercise into 36,529 shares across transactions on June 30 and July 1, 2026. The company withheld 18,514 of those shares to satisfy tax withholding obligations, resulting in withholding proceeds of $214,243 (1,428 shares at $150.03) on 6/30 and $2,917,776 (17,086 shares at $170.77) on 7/01 — total withholding value $3,132,019. Net new shares retained by AmirAli after withholding: 18,015.

Key Details

• Transaction dates and prices:
  • 2026-06-30: 2,817 derivative shares converted (acquired); 1,428 shares withheld @ $150.03 = $214,243 (tax withholding).
  • 2026-07-01: 23,997 and 9,715 derivative shares converted (acquired); 17,086 shares withheld @ $170.77 = $2,917,776 (tax withholding).
• Transaction codes: M = exercise/conversion of derivative (RSU conversion), F = payment of tax liability via share withholding.
• Shares owned after transaction: not specified in this filing.
• Footnotes:
  • F1: Company retained shares to meet the award-holder’s tax withholding obligation; retention amount not in excess of tax liability.
  • F2: Some shares stem from an RSU grant on March 17, 2026 that vests in quarterly installments (Mar 31, Jun 30, Sep 30, Dec 31, 2026).
  • F4/F5: Other converted RSUs relate to earlier grants (Mar 18, 2024 and Mar 12, 2025) with multi-year vesting schedules.
• Filing date: 2026-07-02 (covers transactions through 6/30–7/01); no late-filing flag noted in the information provided.

Context

• These transactions reflect routine RSU vesting/conversion and net-share settlement for tax purposes (company withheld shares to cover taxes). That withholding is not an open-market sale by the insider and should be viewed as a tax-related disposition rather than a discretionary sale. The material cash-equivalent value here is the ~$3.13M in tax withholding; net shares added to the CEO’s holdings from this vesting were 18,015.